Scott J Cronin, MD | |
985 Berkshire Blvd, Suite 101, Wyomissing, PA 19610-1268 | |
(610) 374-5599 | |
(610) 375-1262 |
Full Name | Scott J Cronin |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 18 Years |
Location | 985 Berkshire Blvd, Wyomissing, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306165105 | NPI | - | NPPES |
1029937620001 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | MD453679 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Reading Hospital | West reading, PA | Hospital |
St Joseph Medical Center | Reading, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Ent Head And Neck Specialists, Pc | 3173500451 | 9 |
News Archive
Patients with high blood pressure are relying solely on medication to reduce their risk of heart attack, stroke and heart failure, rather than decreasing salt intake as instructed by their physicians, according to research presented today at ESC Congress 2018, the annual meeting of the European Society of Cardiology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
According to a new study published today in The Journal of the American Medical Association, patients who have severe obstructive sleep apnea have a significantly higher risk of complications related to their heart in the first 30 days after major surgery.
› Verified 9 days ago
Entity Name | Ent Head & Neck Specialists, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1366496473 PECOS PAC ID: 3173500451 Enrollment ID: O20040706000156 |
News Archive
Patients with high blood pressure are relying solely on medication to reduce their risk of heart attack, stroke and heart failure, rather than decreasing salt intake as instructed by their physicians, according to research presented today at ESC Congress 2018, the annual meeting of the European Society of Cardiology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
According to a new study published today in The Journal of the American Medical Association, patients who have severe obstructive sleep apnea have a significantly higher risk of complications related to their heart in the first 30 days after major surgery.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Scott J Cronin, MD 985 Berkshire Blvd, Suite 101, Wyomissing, PA 19610-1268 Ph: (610) 374-5599 | Scott J Cronin, MD 985 Berkshire Blvd, Suite 101, Wyomissing, PA 19610-1268 Ph: (610) 374-5599 |
News Archive
Patients with high blood pressure are relying solely on medication to reduce their risk of heart attack, stroke and heart failure, rather than decreasing salt intake as instructed by their physicians, according to research presented today at ESC Congress 2018, the annual meeting of the European Society of Cardiology.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
According to a new study published today in The Journal of the American Medical Association, patients who have severe obstructive sleep apnea have a significantly higher risk of complications related to their heart in the first 30 days after major surgery.
› Verified 9 days ago
Dr. Joseph R Watson, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Granite Point Dr, Suite 300, Wyomissing, PA 19610 Phone: 610-376-3738 Fax: 610-376-4780 | |
Chetan Y. Safi, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 985 Berkshire Blvd Ste 101, Wyomissing, PA 19610 Phone: 610-374-5599 Fax: 610-375-1262 | |
Dr. Jeffrey S. Driben, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 985 Berkshire Blvd, Ste 101, Wyomissing, PA 19610 Phone: 610-374-5599 Fax: 610-288-8075 | |
Dr. Charles K. Lutz, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 985 Berkshire Blvd, Ste 101, Wyomissing, PA 19610 Phone: 610-374-5599 Fax: 610-288-8075 | |
Dr. Gianfranco Toso, M.D., D.D.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Granite Point Dr, Suite 300, Wyomissing, PA 19610 Phone: 610-376-3738 Fax: 610-376-4780 | |
Dr. Winifred W Kao-seda, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1 Granite Point Dr, Suite 300, Wyomissing, PA 19610 Phone: 610-376-3738 Fax: 610-376-4780 |